---
title: Defending Premium Oncology Pricing via RWE
description: Discover how a global pharma leader used RWE and outcome-based contracting to protect premium oncology pricing and accelerate market access in Europe.
---

[Insights: Client Case Studies ](https://www.quantum-growth.io/insights)

# [Defending Premium Oncology Pricing via RWE](https://www.quantum-growth.io/insights/real-world-evidence-oncology-premium-pricing-market-access)

 Written by [Thierry Laugerette](https://www.quantum-growth.io/insights/author/thierry) | March 14 2026

As payers increasingly challenge the gap between trial data and real-world outcomes, defending premium oncology pricing requires more than clinical evidence — it demands transparency. This case study explores how a global pharmaceutical leader partnered with QUANTUM to deploy a Real-World Evidence framework that protected premium pricing, eliminated payer uncertainty, and accelerated first-line therapy status by six months.

# How Real-World Evidence Defended Premium Oncology Pricing: A Market Access Case Study

## The Challenge

A global pharmaceutical leader launched a breakthrough oncology therapy. Despite superior Phase III trial results, national payers in Europe were demanding a 30% discount, citing "uncertainty" in real-world clinical settings compared to controlled trials. The client risked losing millions in annual revenue and faced a potential "price-anchor" that would affect their global launch.

## The Solution

- **The QUANTUM Solution:** We implemented a **Real-World Evidence (RWE) Hub** to bridge the data gap. 
    - **Automated Data Integration:** We built a secure pipeline to ingest anonymized patient data from participating hospital EHRs (Electronic Health Records).
    - **Risk-Sharing Framework:** We designed an "Outcome-Based Contract" where the client agreed to a "pay-for-performance" model. If the therapy didn't meet specific survival milestones in the real world, the hospital received a rebate.
    - **Executive Dashboard:** We provided payers with a real-time dashboard to monitor therapy efficacy across the patient population, removing the "data black box."

## The Impact

- - **Price Protection:** The client successfully defended their premium price, avoiding the 30% discount.
    - **Market Access:** Secured "First-Line" therapy status 6 months earlier than projected.
    - **Scalability:** The RWE framework was adopted as the global standard for all future oncology launches within the firm.

[View full post](https://www.quantum-growth.io/insights/real-world-evidence-oncology-premium-pricing-market-access)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Thierry Laugerette"
  },
  "dateModified" : "2026-03-14T21:03:43.547Z",
  "datePublished" : "2026-03-14T21:03:43Z",
  "headline" : "Defending Premium Oncology Pricing via RWE",
  "image" : {
    "@type" : "ImageObject",
    "height" : 709,
    "url" : "https://146327097.fs1.hubspotusercontent-eu1.net/hubfs/146327097/Blog%20-%20News%20and%20insights/Defending%20Premium%20Oncology%20Pricing%20via%20RWE.png",
    "width" : 2028
  },
  "mainEntityOfPage" : "https://www.quantum-growth.io/insights/real-world-evidence-oncology-premium-pricing-market-access",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Insights: Client Case Studies"
  }
}
```